Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20788480 | 0.85 | AKR1B1 (0.56) | AKR1B1ALDH1A1MAPTRAB9A | |
| SCHEMBL30529078 | 0.85 | AKR1B1 (0.56) | AKR1B1ALDH1A1MAPTRAB9A | |
| SCHEMBL13870524 | 0.83 | ALDH1A1 (0.67) | AKR1B1ALDH1A1MAPTRAB9A | |
| SCHEMBL1638547 | 0.78 | PRF1 (0.54) | — | |
| SCHEMBL11404428 | 0.78 | ALDH1A1 (0.69) | ALDH1A1MAPTRAB9AHRH1 | |
| SCHEMBL3453563 | 0.78 | NPC1 (0.48) | ALDH1A1MAPTRAB9A | |
| SCHEMBL132696 | 0.76 | MAOB (0.60) | ALDH1A1MAPTRAB9AHRH1 | |
| SCHEMBL29395306 | 0.76 | MAOB (0.60) | ALDH1A1MAPTRAB9AHRH1 | |
| SCHEMBL29799860 | 0.76 | MAOB (0.60) | ALDH1A1MAPTRAB9AHRH1 | |
| SCHEMBL13870536 | 0.76 | HRH1 (0.40) | ALDH1A1MAPTRAB9AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-12-04 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | AKR1B1 606/4885ALDH1A1 1705/4885MAPT 4587/4885 |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | LIPA, PHOSPHO1, MYO1G | AKR1B1 4419/4885ALDH1A1 3679/4885MAPT 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.